

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. to 14. (Cancelled)

15. (Currently Amended) A liposomal-based parenteral composition comprising:

- (a) an aqueous phase comprising an aqueous buffer solution;
- (b) a lipidic phase comprising single bilayered liposomes dispersed within the aqueous phase, wherein said lipidic phase is not a product of reverse-phase evaporation;
- (c) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, said active ingredient being dispersed within the aqueous phase outside of ~~the and not within~~ a liposomes of the lipidic phase; and
- (d) glycine, said glycine being dispersed within the aqueous phase.

16. (Previously Presented) The composition of claim 15, wherein the single bilayered liposomes being made by preparing a solution of the lipidic phase in an alcoholic solvent and injecting the solution under pressure into the aqueous buffer solution contained in a high speed homogenizer.

17. to 18. (Cancelled).

19. (Previously Presented) The composition of claim 15, wherein the aqueous buffer solution is an aqueous phosphate solution.
20. (Previously Presented) The composition of claim 19, wherein said aqueous phosphate solution is selected from the group consisting of a sodium dihydrogen phosphate dihydrate solution, a di-sodium hydrogen phosphate dihydrate solution and mixtures thereof.
21. (Previously Presented) The composition of claim 15, further comprising a preserving agent.
22. (Previously Presented) The composition of claim 15, further comprising an antioxidant.
23. (Previously Presented) The composition of claim 15, further comprising a complexing agent.